Leukemia

Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.

Overall survival results were durable for patients with relapsed/refractory b-cell acute lymphoblastic leukemia when treated with CAR-T cell therapy, Tecartus.

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

After being diagnosed with leukemia, my Golden Retriever, Payton, was my emotional caregiver and gave me the will to live.

My friend, Kevin, was like a brother to me, so I cursed cancer when he died, yet am thankful for the time that we had together.

Patients with blood cancer may develop serious infections after transplants, but a T-cell therapy may improve symptoms and side effects.

The injection Lumoxiti, which was approved for patients with relapsed or refractory hairy cell leukemia, will be pulled from the U.S. market later this year, although alternative therapies are available.

When I experienced an alcohol and cancer relapse, I fell into a depression. Thankfully, clinicians, loved ones and medicine helped.

Life looks a bit different after my cancer diagnosis and the COVID-19 pandemic, making me even more grateful for the people in my life.

I’ve been watching a YouTube channel about Borneo orangutans, and realized that these animals remind me of myself after cancer.

From ballooning ankles to rashes, there were multiple chemotherapy side effects that I had to deal with — here’s how I did it.

Children with acute lymphoblastic leukemia had a 2.4-fold greater risk of relapse if they were considered extremely obese while undergoing maintenance therapy.

Rezlidhia was approved for patients with acute myeloid leukemia based on study results showing that more than one-third of patients experienced a complete remission after taking the drug.

As a recovering addict, I was nervous about the painkillers that would come alongside my cancer treatment, but I soon learned that they would be needed.

Though remission rates for children who underwent CAR-T cell therapy did not differ based on socioeconomic status, accessibility gaps remain.

After being diagnosed with cancer 13 years ago, I began to wonder if my diet had anything to do with it — so I made some changes to eat better.

“Was I OK with dying? Would I still be there for my dog? Can I still smoke?” — all these thoughts entered my mind when my oncologist told me that I had leukemia.

Compared with tissue biopsies, liquid biopsies performed with blood samples may inform cancer teams of a patient’s increased risk for blood cancers, although all patients may not have this risk.

The FDA granted a priority review to the oral drug quizartinib for the treatment of a form of acute myeloid leukemia, one of the more common types of leukemia.

After breaking 20 years of sobriety, I received even worse news: my leukemia had relapsed, and I’d need a bone marrow transplant. Thankfully, my family and treatment team lifted me up during this difficult time.

I’ve had leukemia for 13 years, and don’t owe anyone an explanation why my hair is short, or my face looks puffy.

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

In this poem, I chronicle "Suzy Q's" experience with acute lymphoblastic leukemia.

Patients with blood cancer who have higher levels of neurofilament light chains — which indicate brain injury — were found to be more likely to develop neurotoxicity after CAR-T cell therapy, according to recent research.

From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

From “Good Morning America” host Robin Roberts stepping away from the show after her partner finished breast cancer radiation to a former Tampa Bay Buccaneer dying of leukemia, here is what’s happening in the cancer space this week.

Patients with blastic plasmacytoid dendritic cell neoplasms can enroll in the ongoing CADENZA trial, which is investigating the safety and efficacy of the novel agent pivekimab sunirine in patients with the rare blood cancer.

The FDA’s decision allows patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome — types of blood cancer — to continue enrolling on the TakeAim Leukemia trial.

The Food and Drug Administration put a full clinical hold on a study of the novel drug FHD-286 in patients with acute myelogenous leukemia and myelodysplastic syndrome after study data showed an increase in a potentially fatal side effect.

Adding the investigational cancer drug lanraplenib to Xospata, if found to be effective, may broaden treatment options for patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.